POCI Q3 2026 Earnings Transcript

Precision Optics reported record quarterly revenue of $8.7 million, up 108% year over year, and turned positive on adjusted EBITDA at $300 thousand versus losses in prior periods. Gross margin expanded to 23.6% from 10% a year ago, while full-year revenue guidance was raised to $29 million-$31 million and adjusted EBITDA guidance was narrowed to a $2.5 million-$2.7 million loss. Management also highlighted a strengthened $10 million cash raise, record backlog, and multiple new programs expected to move into production over the next six months.

Analysis

POCI is crossing from “story stock” to “operating leverage stock,” and that changes the tape. The key second-order effect is that each incremental dollar of production now has a much higher pass-through to EBITDA because the cost base is already largely in place; that means the market will likely start discounting forward profitability faster than reported revenue growth alone would suggest. The biggest re-rating catalyst is not the current quarter itself, but the proof that new programs can enter production without collapsing yields or requiring a step-change in headcount.

The near-term bear case is not demand, it’s mix and timing. Aerospace appears vulnerable to an inventory digestion pause over the next 1-2 quarters, which could create a misleading deceleration just as investors start to extrapolate the inflection. At the same time, tariff-credit mechanics create a reporting noise floor: some revenue gets shifted out of the top line when credits are issued, so headline growth may understate underlying unit momentum in a few quarters.

The real strategic variable is whether Unity becomes a repeatable customer-acquisition engine or stays a one-off. Management now has a better product-market wedge, but the pipeline is still too thin for the platform story to matter independently; if Unity converts even 2-3 of the current prospects, the market will likely assign a higher multiple to future development revenue because it reduces time-to-production and raises the probability of recurring manufacturing pull-through. If not, the valuation will revert to a cyclical niche manufacturer with lumpy program ramps.

Consensus is probably underestimating how much the company has de-risked its balance sheet and manufacturing credibility in one move. The capital raise plus positive EBITDA should improve supplier terms and financing flexibility, which matters for a small-cap hardware name where working capital can choke growth before demand does. The opportunity is to own the operating inflection early, but the mistake would be to model linear upside from here; the stock will likely move in bursts around new program conversions and yield milestones rather than a smooth grind.

Key Decisions for Investors

• Long POCI on a 3-6 month horizon into any post-earnings pullback: risk/reward favors upside if the market begins capitalizing positive EBITDA and 29-31M revenue guide as a durable inflection; use the aerospace slowdown as the key downside check.
• Buy POCI call spreads expiring 4-6 months out, ideally strikes just above current implied-volatility pricing: captures re-rating from operating leverage while limiting damage if aerospace pauses create a one-quarter revenue air pocket.
• Pair trade: long POCI / short a less operationally leveraged small-cap medtech hardware peer with similar revenue growth but weaker margin trajectory: thesis is that POCI’s margin inflection should outrun “growth only” names over the next 2 quarters.
• Trim or hedge into strength if the stock trades as if Q3 margins are the new run-rate: the likely setup is a sharp move on guide-up, followed by digestion when tariff credits and aerospace pullback hit reported revenue.
• Track Unity conversion as the catalyst dashboard; if 2+ of the current 4 prospects enter the engineering pipeline within 90 days, add to the position because that is the first evidence the platform can expand TAM rather than just improve execution.